Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for heartburn sufferers: study tests combo therapy for NERD

NCT ID NCT07174882

Disease control Sponsor: I.M. Sechenov First Moscow State Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing a new combination treatment for non-erosive reflux disease (NERD), a common form of GERD that causes heartburn and other symptoms. The treatment adds therapies to strengthen the esophagus's natural barrier on top of standard acid-reducing medication. Researchers will track symptom changes and measure improvements in the esophageal lining in 60 adults over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
complex therapy (acid-suppressive medication plus treatments to strengthen esophageal lining)
What this could lead to
If successful, this could point toward a more effective treatment for NERD, especially for patients who don't get relief from standard acid-blocking drugs.
What could go wrong
This is a small, early-stage study with only 60 participants, so results may not apply to everyone. The complex therapy may not prove better than standard care, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

60 people

The number who actually took part.

Started

Feb 2023

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Outpatient both gender from 18 to 75 years old

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The availability of written informed consent from the patient to participate in the study. 2. Patients aged over 18 years. 3. Gender: both men and women. 4. The patient must be able to independently fill out questionnaires and assess their condition using scales. 5. A confirmed diagnosis of non-erosive reflux disease. Exclusion Criteria: 1. The voluntary withdrawal of consent to participate in the study by the patient. 2. Pregnancy. 3. The patient experienced a serious adverse event, the relationship of which to the study drug is classified as definite, probable, or possible. 4. The patient is receiving/requires additional treatment that may affect the efficacy parameters being studied. 5. Protocol violations that, in the opinion of the investigator, are significant for the results of the clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastroesophageal reflux disease (GERD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastroesophageal reflux disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastroesophageal reflux disease (GERD) Non-erosive gastro-esophageal reflux disease

Contacts and locations

Locations

  • V.Kh.Vasilenko Clinic of Propedeutics of Internal Diseases, Gastroenterology and Hepatology, I.M.Sechenov First Moscow State Medical University (Sechenov University). Gastroenterology department, outpatient clinic.

    Moscow, 119991, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.